The role of glutamine synthetase expression and cystine/glutamate transporter (SLC7A11, xCT) in epilepsy pathogenesis of patients with supratentorial brain gliomas
M. Yu. Prokudin,
B. V. Martynov,
A. I. Yakovenko,
I. V. Litvinenko,
V. Yu. Lobzin,
D. V. Svistov,
V. S. Chirskiy,
K. A. Chemodakova,
O. А. Klitsenko https://doi.org/10.17749/2077-8333/epi.par.con.2022.118
Abstract
Background. Epileptic seizures represent one of the leading clinical manifestations of glial brain tumors that develop on average in 51% of cases. In gliomas, epileptogenesis is quite complex and multifactorial.
Objective: to study a role of the expressed glutamine synthetase enzyme, as well as cystine/glutamate transporter (xCT system, SLC7A11) in the pathogenesis of epilepsy developing in patients with cerebral gliomas.
Material and methods. The study included 32 patients with supratentorial gliomas. The average age of the disease onset (diagnosis) was 50.69±18.01 years. All patients underwent inpatient examination and treatment at the Neurosurgery and Nervous Diseases Clinics of Kirov Military Medical Academy from 2018 to 2020. In all cases, a biopsy of tumor tissue was collected. Histological and immunohistochemical studies were performed (expression of glutamine synthetase and cystine/ glutamate transporter (SLC7A11, xCT)).
Results. Significant (ANOVA p=0.027, Mann–Whitney U-test p=0.033) differences in the expression of cystine/glutamate transporter (xCT system, SLC7A11) were revealed, by showing the following median values (lower quartile; upper quartile): 50% (45; 75) in the group of patients with seizures, 40% (40; 50) in the seizure-free group. The expression level of glutamine synthetase did not significantly differ in the groups with and without seizures.
Conclusion. The data obtained confirmed that one of the pathogenetic mechanisms for epilepsy development in patients with gliomas was related to highly expressed cystine/glutamate transporter (xCT system, SLC7A11) and, as a consequence, an increase in the extracellular glutamate level.
About the Authors
M. Yu. Prokudin
Kirov Military Medical Academy
Russian Federation
Russian Federation
Mikhail Yu. Prokudin – MD, PhD, Faculty Member, Chair of Nervous Diseases
Saint Petersburg, Russia
RSCI SPIN-code: 4021-4432
B. V. Martynov
Kirov Military Medical Academy
Russian Federation
Russian Federation
Boris V. Martynov – Dr. Med. Sc., Associate Professor, Neurosurgeon
Saint Petersburg
RSCI SPIN-code: 9953-3997
A. I. Yakovenko
Kirov Military Medical Academy
Russian Federation
Russian Federation
Andrey I. Yakovenko – MD, PhD, Head of Pathomorphological Department, Central Pathology Laboratory
Saint Petersburg
RSCI SPIN-code: 5937-8120.
I. V. Litvinenko
Kirov Military Medical Academy
Russian Federation
Russian Federation
Igor V. Litvinenko – Dr. Med. Sc., Professor, Head of Chair of Nervous Diseases
Saint Petersburg
WoS ResearcherID: F-9120-2013;
Scopus Author ID: 35734354000;
RSCI SPIN-code: 6112-2792.
V. Yu. Lobzin
Kirov Military Medical Academy; Mechnikov North-Western State Medical University; Children's Research and Clinical Center for Infectious Diseases, FMBA of Russia
Russian Federation
Russian Federation
Vladimir Yu. Lobzin – Dr. Med. Sc., Professor, Chair of Nervous Diseases; Professor, Chair of Neurology; Senior Researcher, Research Department of Neuroinfections and Organic Pathology of the Nervous System
Saint Petersburg
WoS ResearcherID: I-4819-2016;
Scopus Author ID: 57203881632;
RSCI SPIN-code: 7779-3569.
D. V. Svistov
Kirov Military Medical Academy;
Russian Federation
Russian Federation
Dmitriy V. Svistov – MD, PhD, Associate Professor, Head of Chair of Neurosurgery; Chief Neurosurgeon of the Ministry of Defense of the Russian Federation
Saint Petersburg
RSCI SPIN-code: 3184-5590.
V. S. Chirskiy
Kirov Military Medical Academy
Russian Federation
Russian Federation
Vadim S. Chirskiy – Dr. Med. Sc., Head of Chair of Pathological Anatomy; Head of Department, Central Pathology Laboratory of the Ministry of Defense of the Russian Federation
Saint Petersburg
Moscow, Russia
RSCI SPIN-code: 7295-3369.
K. A. Chemodakova
Kirov Military Medical Academy
Russian Federation
Russian Federation
Ksenia A. Chemodakova – Neurosurgeon, Neurosurgery Clinic
Saint Petersburg
RSCI SPIN-code: 8425-1808.
O. А. Klitsenko
Mechnikov North-Western State Medical University
Russian Federation
Russian Federation
Olga A. Klitsenko – PhD (Biol.), Associate Professor, Chair of Pedagogy, Philosophy and Law
Saint Petersburg
RSCI SPIN-code: 7354-3080.
References
1. Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68 (6): 394–424. https://doi.org/10.3322/caac.21492.
2. Ostrom Q.T., Cioffi G., Gittleman H., et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 2019; 21 (Suppl. 5): v1–100. https://doi.org/10.1093/neuonc/noz150.
3. Prokudin M.Yu., Odinak M.M., Litvinenko I.V., et al. Clinical and morphological risk factors for epilepsy in patients with glial and metastatic brain tumors. S.S. Korsakov Journal of Neurology and Psychiatry. 2020; 120 (11): 22–8 (in Russ.). https://doi.org/10.17116/jnevro202012011122.
4. Liubinas S.V., O’Brien T.J., Moffat B.M., et al. Tumour associated epilepsy and glutamate excitotoxicity in patients with gliomas. J Clin Neurosci. 2014; 21 (6): 899–908. https://doi.org/10.1016/j.jocn.2014.02.012.
5. Buckingham S.C., Campbell S.L, Haas B.R., et al. Glutamate release by primary brain tumors induces epileptic activity. Nat Med. 2011; 17 (10): 1269–74. https://doi.org/10.1038/nm.2453.
6. Toledo M., Sarria-Estrada S., Quintana M., et al. Prognostic implications of epilepsy in glioblastomas. Clin Neurol Neurosurg. 2015; 139: 166–71. https://doi.org/10.1016/j.clineuro.2015.10.002.
7. Litvinenko I.V., Vorob’ev S.V., Lobzin V.Iu., Lupanov I.A. Possibilities of pharmacological modulation of brain glutamatergic system in the treatment of vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2013; 113 (9): 29–35 (in Russ.).
8. Litvinenko I.V., Krasakov I.V., Bisaga G.N., et al. Modern conception of the pathogenesis of neurodegenerative diseases and therapeutic strategy. S.S. Korsakov Journal of Neurology and Psychiatry. 2013; 117 (6-2): 3–10 (in Russ.). https://doi.org/10.17116/jnevro2017117623-10.
9. Rosati A., Poliani P.L., Todeschini A., et al. Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. Neuro Oncol. 2013; 15 (5): 618–25. https://doi.org/10.1093/neuonc/nos338.
10. Rosati A., Marconi S., Pollo B., et al. Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. J Neurooncol. 2009; 93 (3): 319–24. https://doi.org/10.1007/s11060-008-9794-z.
11. Sørensen M.F., Heimisdόttir S.B., Sørensen M.D., et al. High expression of cystin-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma. J Neurooncol. 2018; 138 (1): 49–53. https://doi.org/10.1007/s11060-018-2785-9.
12. Robert S.M., Buckingham S.C., Campbell S.L., et al. SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. Sci Transl Med. 2015; 7 (289): 289ra86. https://doi.org/10.1126/scitranslmed.aaa8103.
13. Behrens P.F., Langemann H., Strohschein R., et al. Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study. J Neurooncol. 2000; 47 (1): 11–22. https://doi.org/10.1023/a:1006426917654.
14. Neal A., Moffat B.A., Stein J.M., et al. Glutamate weighted imaging contrast in gliomas with 7 Tesla magnetic resonance imaging. Neuroimage Clin. 2019; 22: 101694. https://doi.org/10.1016/j.nicl.2019.101694.
15. Kempski O., Staub F., Jansen M., Baethmann A. Molecular mechanisms of glial cell swelling in acidosis. Adv Neurol. 1990; 52: 39–45.
16. Beaumont A., Whittle I.R. The pathogenesis of tumour associated epilepsy. Acta Neurochir (Wien). 2000; 142 (1): 1–15. https://doi.org/10.1007/s007010050001.
17. Patt S., Steenbeck J., Hochstetter A., et al. Source localization and possible causes of interictal epileptic activity in tumor-associated epilepsy. Neurobiol Dis. 2000; 7 (4): 260–9. https://doi.org/10.1006/nbdi.2000.0288.
Review
For citations:
Prokudin M.Yu., Martynov B.V., Yakovenko A.I., Litvinenko I.V., Lobzin V.Yu., Svistov D.V., Chirskiy V.S., Chemodakova K.A., Klitsenko O.А. The role of glutamine synthetase expression and cystine/glutamate transporter (SLC7A11, xCT) in epilepsy pathogenesis of patients with supratentorial brain gliomas. Epilepsy and paroxysmal conditions. 2022;14(2):204-213. (In Russ.) https://doi.org/10.17749/2077-8333/epi.par.con.2022.118
Views: 656
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
